---
search:
  boost: 2 
---

# Hepatic Encephalopathy

This is a subcategory of Gastrointestinal Agents.

## Formulary

### Preferred

| Preferred             | Generic Name | Quantity | Time (Days) |
| :-------------------- | :----------- | :------: | :---------: |
| Lactulose             |              |          |             |
| Xifaxan <sup>ST</sup> |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
|               |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Step Therapy

Step Therapy Approval Criteria

- Must have had an inadequate clinical response of at least **14 days** with at least **one**
preferred drug

### Rifaxamin (Xifaxan)

Rifaxamin (Xifaxan) Criteria

- Must have had an inadequate clinical response of at least **14 days** to lactulose to be authorized for monotherapy or add on therapy

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **14 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=64)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=23)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
